Of rats and schizophrenia

Journal of Psychiatry and Neuroscience

Volumn 32, Issue 1, 2007, Pages 8-10

  Boksa, Patricia ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Animal models; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CANNABIS; CLOZAPINE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; PHENCYCLIDINE; PSYCHEDELIC AGENT; PSYCHOSTIMULANT AGENT;

CLINICAL EFFECTIVENESS; COGNITION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; EDITORIAL; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EXTRAPYRAMIDAL SYMPTOM; GENETIC SUSCEPTIBILITY; HUMAN; NERVE CELL PLASTICITY; NONHUMAN; PATHOPHYSIOLOGY; PERCEPTION; RECEPTOR BLOCKING; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 33847056689     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (26)

1. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1:133-52.
2. Bai O, Zhang H, Li XM. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res 2004;1010:81-6.
3. Anis NA, Berry SC, Burton NR, et al. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 1983;79:565-75.
4. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-10.
5. Bai YM, Lin CC, Chen JY, et al. Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry 2006;163:1276-9.
6. Hagan JJ, Jones DN. Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr Bull 2005;31:830-53.
7. Hajos M. Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery. Trends Pharmacol Sci 2006;27:391-8.
8. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160:636-45.
9. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev 2000;31:371-84.
10. Pierce RC, Kalivas PW. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev 1997;25:192-216.
11. Goldman-Rakic PS, Castner SA, Svensson TH, et al. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 2004;174:3-16.
12. Grace AA, Rosenkranz JA. Regulation of conditioned responses of basolateral amygdala neurons. Physiol Behav 2002;77:489-93.
13. Grace AA. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res Brain Res Rev 2000;31:330-41.
14. Lipska BK. Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J Psychiatry Neurosci 2004;29:282-6.
15. Ishizuka K, Paek M, Kamiya A, et al. A review of Disrupted-In- Schizophrenia-1 (DISC1): neurodevelopment, cognition, and mental conditions. Biol Psychiatry 2006;59:1189-97.
16. Chen J, Lipska BK, Weinberger DR. Genetic mouse models of schizophrenia: from hypothesis-based to susceptibility gene-based models. Biol Psychiatry 2006;59:1180-8.
17. Flint J, Valdar W, Shifman S, et al. Strategies for mapping and cloning quantitative trait genes in rodents. Nat Rev Genet 2005;6:271-86.
18. Darvasi A. Dissecting complex traits: the geneticists' "Around the world in 80 days." Trends Genet 2005;21:373-6.
19. Boksa P. Animal models of obstetric complications in relation to schizophrenia. Brain Res Brain Res Rev 2004;45:1-17.
20. Boksa P, Luheshi GN. On the use of animal modeling to study maternal infection during pregnancy and prenatal cytokine exposure as risk factors for schizophrenia. Clin Neurosci Res 2003;3:339-46.
21. Rodriguez De Fonseca F, Gorriti MA, Bilbao A, et al. Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia. Neurotox Res 2001;3:23-35.
22. Kolb B, Gorny G, Limebeer CL, et al. Chronic treatment with Delta-9-tetrahydrocannabinol alters the structure of neurons in the nucleus accumbens shell and medial prefrontal cortex of rats. Synapse 2006;60:429-36.
23. Schneider M, Koch M. The effect of chronic peripubertal cannabinoid treatment on deficient object recognition memory in rats after neonatal mPFC lesion. Eur Neuropsychopharmacol 2007;17:180-6.
24. Szyf M, Weaver IC, Champagne FA, et al. Maternal programming of steroid receptor expression and phenotype through DNA methylation in the rat. Front Neuroendocrinol 2005;26:139-62.
25. Arguello PA, Gogos JA. Modeling madness in mice: one piece at a time. Neuron 2006;52:179-96.
26. Powell CM. Miyakawa. Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder? Biol Psychiatry 2006;59:1198-207.